By Sree Roy With Zepbound (tirzepatide), the first FDA-approved GLP-1 for obstructive sleep apnea (OSA), showing strong reductions in the apnea-hypopnea index (AHI) in patients with obesity, 1 its easy to see why the public misperception that OSA is simply a weight problem is being reinforced
Late-stage trials are tracked on ClinicalTrials.gov
We are NURSE PRESCRIBED so you can be confident you are in safe hands
On the same date, Julian Gill also requested case numbers for all adverse events in the FAERS system related to tirzepatide and semaglutide products produced by Empower Pharmacy in Houston, Texas (both the 503A and 503B products). Noa Metta submitted on September 24 a request for FDA Form 483 inspection reports, warning letters, Establishment Inspection Reports, and adverse event reports relating to pharmacies conducting unauthorized compounding practices, involving semaglutide, tirzepatide, or similar drugs, between January 1, 2022, and the present. Several additional requests addressed non-compounding issues related to GLP-1 drugs, two mentioning Eli Lilly and one mentioning Ozempic and Wegovy